Funding Opportunity

Funding Opportunity Announcement (FOA) for Longevity Research

Purpose: 

The NIA-supported Longevity Consortium is pleased to announce the availability of Translational Opportunity Funds (TOF) to support research aimed at expanding and translating the work of NIA-funded studies on Exceptional Longevity (EL). The intent of this TOF opportunity is to engage the broader scientific community in studies of longevity by bringing new scientists, ideas and resources into the Longevity Consortium (LC). Consequently eligibility for this TOF opportunity is limited to researchers not currently affiliated with labs run by LC researchers. The opportunity is also limited to Institutions in the United States and non-domestic (non-U.S.) components of U.S. Organizations and foreign institutions are not eligible.

Background: 

NIA, with its longstanding interest in discovering and translating genetic and other factors linked to the phenotype of exceptional longevity, has been supporting large-scale human cohort studies on centenarians and exceptionally long-lived individuals since 2004. Over several years, the NIA has built a collection of human longevity-focused translational research projects (such as the Long Life Family Study (LLFS), Longevity Consortium (LC), Longevity Genomics (LG), and Integrative Longevity Omics (ILO) studies), which have performed extensive phenotypic characterization of their cohorts, including developing a Healthy Aging Index (HAI), and have utilized technologies to generate large omics data sets from the genome to the phenome. The primary goal of these longevity projects is to unravel the complex functional relationships across layers of biological information and regulatory processes that influence cellular functions, as reflected in the phenome. In addition to human cohort analyses, some studies have also conducted cross-species multi-omic analyses using data from humans and non-human species that differ widely in lifespan. These projects aim to identify protective factors or mechanisms that contribute to an exceptional life span and health span, to discover druggable targets for interventions that promote healthy aging and extend life span. 

Research Requirements for this FOA:

The NIA Longevity Consortium is seeking projects that build upon and expand the current NIA-funded  research on Exceptional Longevity. Investigators are strongly encouraged to make use of existing controlled-access datasets and samples and/or make use of controlled-access data or samples for which the investigator(s) has a current data use and/or biospecimen use agreement already in place. In addition, the LC encourages investigators to make use of publicly available data sets. 

For this particular opportunity the LC is looking for projects that can exploit existing stored human biospecimens to explore variation in biochemical or physiological traits known as Aging Rate Indicators (ARIs). Successful applications should have high and immediate relevance to the basic biology of aging, extend concepts from the NIA Exceptional Longevity program to additional human cohorts or to animal models, use rigorous research methods, and have a high likelihood of producing preliminary data for future grant proposals focused on the concept of ARIs.

Applicant organizations and investigators must be eligible for NIH funding and must be researchers not affiliated with the labs of current Longevity Consortium researchers.

An “ARI” is conceived to be a biochemical or physiological trait that can discriminate between normal individuals (humans or mice, for example) and those that are aging more slowly.  As discussed in more detail in a recent review paper (Austad et al., 2026; Aging rate indicators and the search for anti-aging drugs.  Frontiers in Science), many properties of fat, brain, muscle, liver and plasma are altered in mice whose aging rate has been slowed by mutant genes, by calorie-restriction and amino acid-restriction diets, and by drugs like rapamycin and SGLT2 inhibitors.  Proteomic and metabolomic data from mouse plasma have also been shown to discriminate slow-aging mice from normal controls (Badenoch et al., 2026: Multi-Tissue Metabolomic Signatures of Five Longevity Interventions Converge on Ergothioneine and Lipid Remodeling in Male UM-HET3 Mice, Frontiers in Aging in press). ARIs differ from biomarkers of age in a fundamental way: biomarkers of age depend on the age of the test subject, while ARIs instead provide insight into the subject’s rate of aging at the time the sample is obtained.

This FOA solicits new research proposals aimed at testing, refining, and extending these studies, and in particular at translating the work from mice to studies of humans.  Key questions might include: (a) Do ARIs discovered in mouse plasma provide equivalent information in human samples?  (b) Do interventions that induce favorable changes in ARIs in mice produce corresponding changes in human biospecimens or human cellular systems, including iPSC-derived models?  (c) Can archived, banked human plasma samples, or metabolomic and proteomic data from these samples, identify middle-aged subjects who show minimal age-related changes in the 5 – 20 years since the sample was obtained?  (d) Can patterns of DNA methylation, or other forms of epigenetic change, meet the criteria for ARI status in mice or in humans?  These questions are only examples, and applications that ask other questions related to the ARI concept, ARI candidates, or indicators of the slow-aging state in people would also be welcome.

The LC has identified a number of ARIs in mice and is pursuing studies in humans but would like to evaluate them in a wider variety of settings. Examples of the types of studies suitable for this FOA include, but are not limited to:

  • Population-based studies using extant samples evaluating inter-individual variation in ARI values.

  • Analysis of ARIs using extant samples from a clinical trial exploring an intervention for an age-related disease such as Alzheimer’s, heart disease, or diabetes.

  • Comparison of individual ARI values using extant samples against more traditional aging clocks, such as epigenetic clocks.

  • Evaluation of the reliability of the measurement of ARIs using different assays and spike-in studies and related techniques.

  • Testing proposed ARIs in paired human biosamples collected before and after an intervention.

  • Testing ARIs using specimens from populations with long-term follow-up, to see if a proposed ARI does discriminate slow-aging people from others.

  • Testing ARIs discovered in mouse studies to see if they discriminate between very healthy people from people of average health at ages less than 75 years. 

Eligibility: 

Eligible organizations include domestic Higher Education Institutions and domestic Nonprofits Other Than Institutions of Higher Education. Only Institutions within the United States are eligible to submit an application in response to this FOA. Applications from foreign organizations or with foreign components are not allowed.

Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support. Multi-PI applications are not allowed, but connections between external parties and Longevity Consortium investigators are encouraged. Based on the availability and applications received, this FOA aims to fund an application led by an Early-Stage Investigator and to fund a second application led by an established investigator. Early Stage Investigators (ESI) are defined by the NIH.

Proposed studies must adhere to the research requirements for this FOA. Human clinical trials are considered out of scope for this opportunity. If applicable, the proposed work will comply with the single IRB (sIRB) requirement as mandated by the Longevity Consortium, ensuring centralized ethical oversight across all participating sites.

All applications must comply with NIH guidelines regarding the appropriate use of Artificial Intelligence (AI), including requirements related to restricted data, originality of content, disclosure, confidentiality, and data security.

Proposals, Budget Limits and Number of Awards:  

Proposals are requested with a total cost limit (direct and indirect costs) of up to $132,500, using established DHHS rates for indirect costs, fringe benefits, and salary caps. Two awards are expected to be funded. In rare instances, multi-year proposals are accepted up to a two-year limit. In the project description, aims for subsequent years should build from proof-of-concept and outcomes completed in the prior year. Continuation of TOF projects for the subsequent year will be based on availability of funds and progress made in the prior year. Applications with subawards are not supported.

The anticipated period of performance for awards is February 1 2027  through August 31 2027. Project extensions are not automatic and are subject to NIH approval of unexpended funds. For project proposals involving multiple institutions, please contact Mikasa Morf ([email protected]) for guidance on developing the budget.

Application Process: 

Applications submitted without all of the materials are not able to be considered for review and will not be submitted to the TOF Committee. Investigators should submit a single combined PDF of the following documents via email to Mikasa Morf ([email protected]) and Jennifer Dougherty ([email protected]). The email with the single PDF of the documents must be submitted with the approval of an institutional official.

  • PHS398 Form Page 1 - signed by institutional signing official

  • Performance Site Location Information using Project/Performance Site Format Page

  • Facilities and Resources Document, 1 page maximum

  • Equipment List if applicable, 1 page maximum

  • NIH Common Form Biosketch for Key Personnel, must be certified

  • Maximum three-page description of the project, including: 1) Background and relevance to longevity, 2) succinct description of Approach, 3) potential impact or relevance to the understanding of longevity; 4) how results would provide preliminary data for future grant submissions by NIA’s Exceptional Longevity study investigators; 5) A schematic and figures/tables laying out the work to be pursued as well as reflecting preliminary data and 6) a timeline in the form of a Gantt chart using quarterly intervals  for the completion of key items/products.

  • Maximum of one page for References, including PMCIDs where applicable

  • PHS Human Subjects and Clinical Trials Information form, if applicable

  • Vertebrate Animals document limited to 1 page, if applicable

  • Detailed SF424 R&R Budget and one-page Budget Justification

  • Institutionally negotiated F&A rate agreement

Due Date: December 11, 2026

Formatting:

Adherence to formatting requirements, and page limits noted in the Application Process, is necessary to ensure readability and fairness in review.

  • Font size: Must be at least 11 points. Smaller text in graphics, figures, graphs, diagrams, and charts is acceptable as long as it remains legible at 100% zoom.

  • Some PDF conversion software reduces font size, so it's important to verify that the final PDF meets the font requirements.

  • Type density: Must not exceed 15 characters per linear inch (including characters and spaces).

  • Line spacing: No more than six lines per vertical inch.

  • Text color: No restriction. Although not required, black or other high-contrast text colors are recommended, as they print well and are legible to the largest audience.

  • Follow NIH guidelines for the allowability of hyperlinks.

Merit Review Process: 

Applications will be evaluated by a TOF Committee. Dependent on the number of applications received, the TOF Committee plans approximately 8-10 weeks for the review, selection and notification to the investigators (applicants) and their institutions. The Committee is composed of investigators from the NIA program office, the NIA EL studies, and investigators from the Longevity Consortium’s Observational Study Monitoring Board and/or Pharmaceutical Translational Advisory Panel. Committee members will be selected specific to the expertise in the proposal's subject area.

Review Criteria: 

1) Relevance to understanding the biological basis of longevity; 2) Extends or translates concepts or results from NIA’s EL studies to other populations or from animal models to humans; 3) Utilizes rigorous research methods; and 4) Has potential as preliminary data for grant proposals on longevity. TOF proposals should include some details of an analytical plan, as needed.   

Reporting: 

Investigators from funded TOF projects are required to use Longevity Consortium meetings to present and lead a discussion on the progress of the TOF and the Investigator is required to submit interim and annual progress reports. Results may be posted on one or more websites of the respective NIA EL studies and the NIA ELITE (Exceptional LongevIty Translational rEsources) Portal. NIH data sharing policies apply to these TOF projects. Publications resulting from this project must acknowledge NIH/NIA as a sponsor in any publications or other public products that arise from the funded research.

Inquiries to the FOA: 

Potential applicants are encouraged to contact Drs. Steve Cummings ([email protected]) and Nicholas Schork ([email protected]) to learn more about this funding opportunity and discuss their project ideas. General questions about the LC TOF program should be directed to Jennifer Dougherty ([email protected]). Questions about institutional eligibility, administrative documentation and formatting, and budget/subcontracting requirements should be directed to Mikasa Morf ([email protected]).